CHIH-HSIN YANGSequist L.V.2020-05-262020-05-2620140732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84899668031&doi=10.1200%2fJCO.2013.54.1904&partnerID=40&md5=1eb64750380eda952270517816a92f78https://scholars.lib.ntu.edu.tw/handle/123456789/495024[SDGs]SDG3afatinib; epidermal growth factor receptor; loperamide; afatinib; antineoplastic agent; epidermal growth factor receptor; quinazoline derivative; cancer chemotherapy; clinical trial (topic); diarrhea; diet; drug dose reduction; drug safety; gene mutation; human; letter; priority journal; progression free survival; quality of life; treatment duration; adenocarcinoma; female; genetics; lung adenocarcinoma; lung tumor; male; note; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Quinazolines; Receptor, Epidermal Growth Factorletter10.1200/JCO.2013.54.1904244937332-s2.0-84899668031